Treatment-Resistant Pemphigoid Following SARS-CoV-2 Vaccination
Orange Park Medical Center
Pemphigoid, Bullous Pemphigoid, BP, COVID-19 vaccine adverse effects, SARS-CoV-2, COVID-19, Moderna COVID-19 mRNA vaccine, autoimmune bullous disease, anti-laminin gamma-1 (p200) pemphigoid, p200 pemphigoid
Dermatology | Immune System Diseases | Skin and Connective Tissue Diseases
As the SARS-CoV-2 vaccinated population increases, there have been many reports of vaccine-induced cutaneous reactions but scarce information on vaccine-induced autoimmune bullous disease. Vaccinations have been associated with the unmasking or development of autoimmune bullous disease; however, there is little data on SARS-CoV-2, specifically. We report a rare case of new-onset pemphigoid in a 70-year-old male following the second dose of the mRNA-1273 vaccine. The patient’s disease has been refractory to treatment, thus the underlying pathophysiology in vaccine-induced pemphigoid is likely unique, and further investigation into this pathophysiology is warranted.
Publisher or Conference
Skin: The Journal of Cutaneous Medicine
Altmann S, Jacobs D, Brown T, Kamath P, Krishnamurthy K. Treatment-Resistant Pemphigoid Following SARS-CoV-2 Vaccination. SKIN. 2022;6(3):238-242. doi:10.25251/skin.6.3.10